Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
September 20, 2023

Unlocking Safer Gene Therapies Broken String Biosciences Secures $15M Investment

Safer gene therapies demand rigorous off-target checks in genome editing, like CRISPR-Cas9

Gene therapies are poised to revolutionize medicine, but their safety is paramount. Enter Cambridge-based Broken String Biosciences, a genomics firm striving to make these therapies safer. Recently, they secured a $15 million Series A funding round, co-led by Illumina Ventures and Mérieux Equity Partners, among others. These funds will propel their DNA break mapping platform, INDUCE-seq, towards a scalable 'Platform as a Service' (PaaS), expand its applications beyond gene editing, and bolster the company's growth, including opening a US office. The goal? To unlock the next wave of safer, more efficient, and affordable cell and gene therapies.

In a significant move, Yoann Bonnamour from Mérieux Equity Partners and Arnaud Autret from Illumina Ventures join Broken String Biosciences' Board of Directors, recognizing the platform's potential to become the gold standard for measuring off-target gene editing, a critical factor in advancing gene therapy.

Gene therapies hold immense promise, but safety is paramount. Cambridge-based Broken String Biosciences is dedicated to making gene therapies safer through its genomics technology. Recently securing a $15 million Series A funding round co-led by Illumina Ventures and Mérieux Equity Partners, among others, the company is set to expand its DNA break mapping platform, INDUCE-seq, into a scalable 'Platform as a Service' (PaaS) and broaden its applications beyond gene editing. This investment supports their mission to unlock the next wave of safer, efficient, and affordable cell and gene therapies. The addition of Yoann Bonnamour and Arnaud Autret to the company's Board of Directors signals the platform's potential to become the industry standard for measuring off-target gene editing, a pivotal step in advancing gene therapy.

Neil Hodgson Coyle
Neil Hodgson-Coyle
Editorial chief at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram